Transforming oncology with antibody therapeutics
European Pharmaceutical Review
MAY 4, 2023
Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2012; 23(8): 6 – 9. Cancer Ther.
Let's personalize your content